Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin

  • Authors: Kolbin AS1,2, Mosikyan AA3, Balykina YE2, Proskurin MA2
  • Affiliations:
    1. I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
    2. Saint Petersburg State University
    3. V.A.Almazov National Medical Research Center
  • Issue: Vol 20, No 1 (2018)
  • Pages: 64-69
  • Section: Articles
  • URL: https://modernonco.orscience.ru/1815-1434/article/view/27173
  • Cite item

Abstract


Background. Nowadays there are no any standards of treatment for patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin. Ixabepilone has proved successful as a single agent for treatment of these patients. Methods. Eribulin was chosen as an alternative strategy. Efficacy criteria were overall and progression-free survival. Cost-effectiveness analysis is performed on the basis of published data and Markov modeling for 1.5 year time horizon. Results. Total expenditures for ixabepilone strategy were 18.2% less than those for eribulin treatment. Administration of ixabepilone instead of eribulin will allow treating additionally up to 222 patients per year. Price elasticity analysis revealed that total expenditures on ixabepilone will be 20% less than on eribulin treatment at a price of ixabepilone equal to 63 000 rubles per 45 mg vial and 21 691.23 rubles per 15 mg vial of ixabepilone. Conclusion. Ixabepilone as a single agent appeared to be economically reasonable as compared to eribulin in case of ineffective pretreatment with taxanes, anthracyclines and capecitabine.

Full Text

Restricted Access

About the authors

A S Kolbin

I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation; Saint Petersburg State University

Email: alex.kolbin@mail.ru
199034, Russian Federation, Saint Petersburg, Universitetskaia nab., 7/9

A A Mosikyan

V.A.Almazov National Medical Research Center

197341, Russian Federation, Saint Petersburg, ul. Akkuratova, 2

Y E Balykina

Saint Petersburg State University

199034, Russian Federation, Saint Petersburg, Universitetskaia nab., 7/9

M A Proskurin

Saint Petersburg State University

199034, Russian Federation, Saint Petersburg, Universitetskaia nab., 7/9

References

  1. Zeichner S.B, Ambros T, Zaravinos J et al. Defining the survival benchmark for breast cancer patients with systemic relapse. Breast Cancer (Auckl) 2015; 9: 9-17.
  2. Zeichner S.B, Herna S, Mani A et al. Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. Breast Cancer Res Treat 2015; 153 (3): 617-24.
  3. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М.: МНИОИ им. П.А.Герцена - филиал ФГБУ «НМИРЦ» Минздрава России, 2018
  4. Стенина М.Б., Жукова Л.Г., Королева И.А., и др. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли. 2017; 3 (Спецвып. 2): 105-34.
  5. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version II. 2017.
  6. Методические рекомендации по проведению сравнительной клинико-экономической оценки лекарственного препарата. ФГБУ ЦЭККМП Минздрава России. M., 2016
  7. Методические рекомендации по оценке сравнительной клинической эффективности и безопасности лекарственного препарата. ФГБУ ЦЭККМП Минздрава России. M., 2016.
  8. Методические рекомендации по оценке влияния на бюджет в рамках реализации программы государственных гарантий бесплатного оказания гражданам медицинской помощи. ФГБУ ЦЭККМП Минздрава России. M., 2016.
  9. Распоряжение Правительства Российской Федерации от 23 октября 2017 г. №2323-р. «Об утверждении перечня жизненно необходимых и важнейших лекарственных препаратов для медицинского применения на 2018 год».
  10. Cortes J, O’Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377: 914.
  11. Колбин А.С., Курылев А.А., Павлыш А.В. и др. Научный анализ исходов в онкологии. Особенности фармакоэкономической экспертизы. Мед. технологии. Оценка и выбор. 2012; 2 (8): 87-93.
  12. Perez E.A, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25 (23): 3407-14.
  13. Center for Drug Evaluation and Research. Application Number 22-065. Medical Review. October 11, 2007.
  14. Pajk B, Cufer T, Canney P et al. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast 2008; 17 (2): 180-5.
  15. Zeichner S.B, Terawaki H, Gogineni K. A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) 2016; 22; 10: 25-36.
  16. Vahdat L.T, Garcia A.A, Vogel C et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat 2013; 140: 341-51.
  17. Манзюк Л.В., Коваленко Е.И., Артамонова Е.В. Эрибулин в лечении метастатического рака молочной железы. Вопр. онкологии. 2015; 2: 195-8
  18. Aftimos P, Awada A. Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next? Adv Ther 2011; 28 (11): 973-85.
  19. Основные понятия в оценке медицинских технологий: метод. пособие. Под. ред. А.С.Колбина, С.К.Зырянова, Д.Ю.Белоусова. М.: Издательство ОКИ, 2013
  20. Park Y.H, Jung K.H, Im S.A et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol 2013; 31: 1732.
  21. Генеральное тарифное соглашение ОМС на 2018 год. URL: spboms.ru
  22. Колбин А.С., Мосикян А.А., Курылев А.А. и др. Фармакоэкономическая оценка применения лекарственного средства иксабепилон (Икземпра) в монотерапии больных местно-распространенным и метастатическим раком молочной железы, резистентным к лечению антрациклинами, таксанами и капецитабином. Современная Онкология. 2017; 19 (1): 45-51

Statistics

Views

Abstract - 25

PDF (Russian) - 2

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies